| Serial Number | 88469477 |
| Word Mark | HYLEUKIN-7 |
| Filing Date | Wednesday, June 12, 2019 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, January 25, 2021 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 28, 2020 |
| Goods and Services | Antibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent for medical purposes, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention, treatment, and cure of diseases and conditions impacting the eyes, ears, nose, mouth and nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for anticancer immunotherapy; Pharmaceutical preparations for digestive organs, namely, for the prevention, treatment, and cure of diseases and conditions impacting digestive organs; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for immunomodulatory purposes, namely, for the regulation of immune functions; Pharmaceutical preparations for immunotherapy; Pharmaceutical preparations for preventing and treating obese; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cervical cancer; Pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; Pharmaceutical preparations for the treatment of cervical pre-cancer; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of head and neck cancer; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for urogenital organs; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for the treatment of viral diseases; Preventive vaccines; Preventive vaccines against human papilloma virus infections; Therapeutic vaccines; Vaccines; Pharmaceutical preparations for the treatment of lymphopenia; Immunoglobulin fusion protein pharmaceutical preparations, namely, antibodyfusion proteins for the treatment of cancer |
| Pseudo Mark | HYLEUKIN- SEVEN |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 24, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Genexine, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Seongnamsi, Gyeonggi 13488 KR |
| Party Name | Genexine, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Seongnamsi, Gyeonggi 13488 KR |
| Event Date | Event Description |
| Monday, January 25, 2021 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, January 25, 2021 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, June 23, 2020 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, April 28, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 28, 2020 | PUBLISHED FOR OPPOSITION |
| Wednesday, April 8, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, March 25, 2020 | ASSIGNED TO LIE |
| Thursday, March 19, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 18, 2020 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, March 18, 2020 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, March 18, 2020 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, March 18, 2020 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, February 24, 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, February 24, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, February 24, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, February 24, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, February 24, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Monday, February 24, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, February 24, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, February 24, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, August 26, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, August 26, 2019 | NON-FINAL ACTION E-MAILED |
| Monday, August 26, 2019 | NON-FINAL ACTION WRITTEN |
| Tuesday, August 20, 2019 | ASSIGNED TO EXAMINER |
| Monday, June 24, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Saturday, June 15, 2019 | NEW APPLICATION ENTERED IN TRAM |